【drug-news】生物技术产业: 谁当总统都行

sunlangwolf

Biotech group not endorsing for prez, but seeks more in FDA budget
By Christine McConville
Thursday, September 4, 2008 - Updated 1d 4h ago
克里斯汀·麦康威尔表示：生物技术产业不在乎谁当总统，只在乎为美国食品药品管理局寻求更多的财政预算
2008年9月4日，星期四---28小时前的消息

The world’s largest biotechnology organization isn’t endorsing a candidate for president.
世界最大的生物技术机构不偏向于支持哪一位候选人当总统。

But when that next U.S. leader is elected, the Biotechnology Industry Organization’s members will call on him to significantly increase the federal Food and Drug Administration’s budget, so it can speed up the review process for cutting-edge medicines now waiting in the pipeline for approval.
但时下正进行下一届美国总统选举，生物技术 产业机构的成员呼吁总统候选人重点增加其在联邦食品药品管理局的财政预算，以加速审批那些正在等候批准的打擦边球的药物。

“Our industry is led by some very, very brilliant scientists,” said Jim Greenwood, president and chief executive of BIO. “But it is critical that the FDA have personnel available to review and understand (their work.)”
生物技术组织的董事长兼首席执行官吉姆·格林伍德指出：“虽然我们产业由一批杰出的科学家领衔，但是问题的严峻之处在于FDA自己有内行的人员进行药品审批。”

Greenwood’s comments were made yesterday in Washington, D.C., during a media briefing on biotech-related legislation.
昨天在华盛顿召开的与生物技术相关立法的媒体通报会上，格林伍德的提出了以上的观点。

Joshua Boger, chairman of BIO’s board and CEO of Cambridge-based Vertex Pharmaceuticals Inc., also participated in the hour-long briefing.
作为生物技术领域的主席和有剑桥背景的Vetex医药公司的首席执行官，约书亚·博格也出席了这一个小时的记者会。

Both men acknowledged that the American public wants health care to be less expensive.
他们都认为现在美国民众为了健康而降低了对药品价格的关注度。

But they said that, from the biotechnology industry’s point of view, there’s not a lot of difference between Democratic presidential nominee U.S. Sen. Barack Obama and Sen. John McCain, the Republican’s pick for president.
但同时他们指出，来自生物技术产业的观点认为，在美国民主党的提名人巴拉克·奥巴玛共和党提名人约翰·麦凯恩之间对此并不存在过多的分歧。

“Both said pretty good things about biotechnology, and both support embryonic stem cell research,” Greenwood said, “and both want to move from an ideological to a science-based policy, and both support more funding for the FDA.
格林伍德说：“两位总统候选人都对生物技术产业做出了美好的承诺，两人都支持胚胎干细胞的研究，并且都希望通过从意识形态方面着手制定一个有科学基础的政策，都将会给FDA提供更多的研究基金。”

“Both support stronger action on global warming and view it as human induced, and both support the development of cellulose ethanol.
“We are not endorsing a candidate because there’s not such a great difference between them,” he said.
他认为，两个候选人都赞成在全球气候变暖的问题上采取更有力的措施，考虑到这一问题是因人类活动导致的，并都支持新燃料纤维素乙醇的发展。

Instead, biotech leaders will press the next president to allocate more money to the FDA to help speed up the drug-review process.
然而，生物技术的领袖将对下一任美国总统施压，让他拨出更多的资金给FDA以助加速药物评审进程。

“The bottom line is we have to help the next administration achieve health-care reform,” Boger said.
博格说，底线是我们务必协助下一届政府完成医疗保健改革。

Part of that reform is letting drug makers create and then sell drugs that reduce suffering and cure diseases, he said. “It is the most straightforward way to reduce medical costs,” he said.
他指出，部分的改革将要放宽药物研发者的创新及销售以减少病患治愈疾病，这是降低药物研发经费的最直接的途径。